Comparison of therapeutic effects of EGFR‐tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function

Publisher： John Wiley & Sons Inc

E-ISSN： 1759-7714|9|2|228-233

ISSN： 1759-7706

Source： Thoracic Cancer, Vol.9, Iss.2, 2018-02, pp. : 228-233

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Detection and monitoring of driver mutations by next‐generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR‐tyrosine kinase inhibitors

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 181-184

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subsequent treatment of epidermal growth factor receptor‐tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 678-686

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinicopathological characteristics and outcomes of ROS1‐rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements

By  

Thoracic Cancer, Vol. 6, Iss. 4, 2015-07 ,pp. : 413-420

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 709-714

John Wiley & Sons Inc

Access to resources Recommend Favorite

Survival analysis of patients with advanced non‐small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi‐center retrospective study

By  

Thoracic Cancer, Vol. 9, Iss. 2, 2018-02 ,pp. : 278-283

John Wiley & Sons Inc

Access to resources Recommend Favorite